DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Dactolisib is an investigational drug.
There have been 4 clinical trials for Dactolisib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 21st 2019.
The most common disease conditions in clinical trials are Respiratory Tract Infections and [disabled in preview]. The leading clinical trial sponsors are Restorbio Inc., National Institute on Aging (NIA), and [disabled in preview].
There are one hundred and thirty-three US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Dactolisib
|A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults||National Institute on Aging (NIA)||Phase 2|
|A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults||Restorbio Inc.||Phase 2|
|Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes||Restorbio Inc.||Phase 3|
Top disease conditions for Dactolisib
Top clinical trial sponsors for Dactolisib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Dactolisib||Start Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|Dactolisib||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|Dactolisib||Start Trial||Antibody drug conjugates||Novartis AG (Basel, CH)||Start Trial|
|Dactolisib||Start Trial||Triazine compounds as PI3 kinase and mTOR inhibitors||Pfizer Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|